US Government As Represented by the Secretary of the Army

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Other

The State University of New York

Kenneth H Eckels

Bruce L Innis

Doria R Dubois

Joseph R Putnak

Charles H Hoke

David Vaughn

J Robert Putnak

Robert M Chanock

Ching-Juh Lai

Alexander G Pletnev

Ruhe Men

Michael Bray

Stephen J Thomas

Yi-Ming Zhang

Yong Cheol Shin

Hyun Su Kim

Sun Pyo Hong

Soo Ok Kim

Sung Hee Lee

Wellington Sun

Niranjan Kanesa-Thasan

Wang Don Yoo

Leonard N Binn

Doris R Dubois

Kevin Cassidy

Sun Wellington

Rafael De La Barrera

Niranjan Kanessa-thasan

Niranian Kanesa-thasan

Erik A Henchai

Ashok K Srivastava

Richard Jarman

Timothy Endy

Joseph B Putnak

Sang Bum Moon

Yong Ju Chung

Joseph R Puniak

The invention generally relates to a purified inactivated Zika virus (ZIKV), methods for producing the purified inactivated ZIKV, immunogenic compositions and vaccines comprising the purified inactivated ZIKV and methods for the prevention and/or treatment of infection by ZIKV.

Zika virus vaccine and methods of production

Immunogenic compositions comprising one or more inactivated dengue viruses and one or more inactivated non-dengue flaviviruses and methods of making and using thereof are provided.

Combination purified inactivated vaccine for flaviviruses

The present invention provides vaccine compositions of attenuated dengue virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against all four dengue virus serotypes by administration of attenuated dengue-1, dengue-2, dengue-3, and dengue-4 virus.

Multivalent dengue virus vaccine

The invention includes a chimeric virus for use in a vaccine preparation having a genome comprising nucleic acid sequences encoding at least one structural protein from one flavivirus and nucleic acid sequences encoding nonstructural protein from another flavivirus. The genome preferably includes mutations within the viral genome that reduce virus virulence and in a particularly preferred embodiment these vaccines are directed to flaviviruses such as dengue virus, tick-borne encephalitis virus and Japanese encephalitis virus. The invention also includes a baculovirus having a recombinant dengue cDNA sequence which encodes: (1) dengue virus capsid protein, pre-matrix protein, envelope glycoprotein and NS1 and NS2a nonstructural proteins or (2) dengue envelope glycoprotein or (3) dengue non-structural proteins NS1 and NS2a. The invention further includes a baculovirus having a recombinant Japanese B encephalitis virus cDNA sequence which encodes the Japanese B encephalitis virus capsid protein, pre-matrix protein, envelope glycoprotein and non-structural proteins NS1 and NS2a. The invention further includes a vaccine and a method to produce that vaccine.

Chimeric and/or growth-restricted flaviviruses

The present invention provides a method for replicating virus to high titer in cultured mammalian cells by infecting the mammalian cells with the high titer virus strain to obtain infected cells, specifically, attenuated dengue virus strains of serotype 1, 2, 3, and 4. The resulting replicated virus is suitable for use in vaccines and vaccination methods which are also provided by the invention.

Adaptation of virus to vertebrate cells

The present invention provides vaccine compositions of attenuated dengue-4 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-4 virus by administration of attenuated dengue-4 virus.

Attenuated dengue-4 virus vaccine

The present invention provides immunogenic compositions of attenuated dengue-1 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-1 virus by administration of attenuated dengue-1 virus.

Attenuated dengue-3 virus vaccine

The present invention provides vaccine compositions of attenuated dengue-2 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-2 virus by administration of attenuated dengue-2 virus.

Attenuated dengue-2 virus vaccine

An attenuated Japanese encephalitis virus adapted to Vero cell by passages on Vero cell is disclosed. A Japanese encephalitis vaccine comprising said attenuated virus is also disclosed.

Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine

An inactivated dengue virus vaccine to immunize and protect humans against dengue fever is described. The vaccine is based on dengue viruses which have been propagated to high titers in suitable cells, purified and inactivated under conditions which destroy infectivity but preserve immunogenicity, a high level of which is demonstrated in animal models.

Inactivated dengue virus vaccine

An inactivated dengue virus vaccine to immunize and protect humans against dengue fever is described. The vaccine is based on dengue viruses which have been propagated to high titers in suitable cells, purified and inactivated under conditions which destroy infectivity but preserve immunogenicity, a high level of which is demonstrated in animal models. Uses of the inactivated dengue virus for detecting antibodies to dengue and kits therefor are also described.

Method and kit for detection of dengue virus

Growing community of inventors

Rockville, MD, United States of America

Kenneth H Eckels